Ispecimen Stock Performance
| ISPC Stock | USD 1.10 0.03 2.80% |
The company retains a Market Volatility (i.e., Beta) of 0.28, which attests to not very significant fluctuations relative to the market. As returns on the market increase, ISpecimen's returns are expected to increase less than the market. However, during the bear market, the loss of holding ISpecimen is expected to be smaller as well. At this point, iSpecimen has a negative expected return of -0.0981%. Please make sure to check out ISpecimen's potential upside, as well as the relationship between the daily balance of power and market facilitation index , to decide if iSpecimen performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days iSpecimen has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, ISpecimen is not utilizing all of its potentials. The current stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
| Begin Period Cash Flow | 2.3 M | |
| Total Cashflows From Investing Activities | 2 M | |
| Free Cash Flow | -8.3 M |
ISpecimen | Build AI portfolio with ISpecimen Stock |
ISpecimen Relative Risk vs. Return Landscape
If you would invest 127.00 in iSpecimen on April 30, 2025 and sell it today you would lose (14.00) from holding iSpecimen or give up 11.02% of portfolio value over 90 days. iSpecimen is currently does not generate positive expected returns and assumes 4.2708% risk (volatility on return distribution) over the 90 days horizon. In different words, 38% of stocks are less volatile than ISpecimen, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ISpecimen Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ISpecimen's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as iSpecimen, and traders can use it to determine the average amount a ISpecimen's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.023
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ISPC |
Estimated Market Risk
| 4.27 actual daily | 38 62% of assets are more volatile |
Expected Return
| -0.1 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average ISpecimen is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ISpecimen by adding ISpecimen to a well-diversified portfolio.
ISpecimen Fundamentals Growth
ISpecimen Stock prices reflect investors' perceptions of the future prospects and financial health of ISpecimen, and ISpecimen fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ISpecimen Stock performance.
| Return On Equity | -2.65 | ||||
| Return On Asset | -0.73 | ||||
| Profit Margin | (1.40) % | ||||
| Operating Margin | (1.55) % | ||||
| Current Valuation | 2.19 M | ||||
| Shares Outstanding | 2.5 M | ||||
| Price To Earning | 0.78 X | ||||
| Price To Book | 1.60 X | ||||
| Price To Sales | 0.33 X | ||||
| Revenue | 9.29 M | ||||
| EBITDA | (12.73 M) | ||||
| Cash And Equivalents | 23.69 M | ||||
| Cash Per Share | 2.67 X | ||||
| Total Debt | 312.17 K | ||||
| Debt To Equity | 0.14 % | ||||
| Book Value Per Share | 0.67 X | ||||
| Cash Flow From Operations | (8.26 M) | ||||
| Earnings Per Share | (11.93) X | ||||
| Total Asset | 9.35 M | ||||
| Retained Earnings | (71.86 M) | ||||
About ISpecimen Performance
By analyzing ISpecimen's fundamental ratios, stakeholders can gain valuable insights into ISpecimen's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if ISpecimen has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if ISpecimen has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts. Ispecimen operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 59 people.Things to note about iSpecimen performance evaluation
Checking the ongoing alerts about ISpecimen for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for iSpecimen help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| iSpecimen generated a negative expected return over the last 90 days | |
| iSpecimen may become a speculative penny stock | |
| iSpecimen has high historical volatility and very poor performance | |
| iSpecimen has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 9.29 M. Net Loss for the year was (12.5 M) with profit before overhead, payroll, taxes, and interest of 3.1 M. | |
| iSpecimen currently holds about 23.69 M in cash with (8.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.67, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| iSpecimen has a frail financial position based on the latest SEC disclosures |
- Analyzing ISpecimen's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ISpecimen's stock is overvalued or undervalued compared to its peers.
- Examining ISpecimen's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ISpecimen's management team can have a significant impact on its success or failure. Reviewing the track record and experience of ISpecimen's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ISpecimen's stock. These opinions can provide insight into ISpecimen's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for ISpecimen Stock analysis
When running ISpecimen's price analysis, check to measure ISpecimen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ISpecimen is operating at the current time. Most of ISpecimen's value examination focuses on studying past and present price action to predict the probability of ISpecimen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ISpecimen's price. Additionally, you may evaluate how the addition of ISpecimen to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |